More Than a Decade of Practice Changing Trials

Nov 26, 2013

Cardiology Magazine

Font Size
A
A
A

By Deepak L. Bhatt, MD, MPH, FACC, Christopher P. Cannon, MD, FACC, and Kim A. Eagle, MD, FACC

 

Additional Content

Some of the hottest practice-changing trials have been presented at the ACC’s Annual Scientific Sessions. Late-Breaking Clinical Trials (LBCTs) were first introduced at ACC’s meeting in 2001, and since their inception, LBCTs have become one of the main reasons hundreds of scientists submit their findings each year for consideration into the ACC’s program. It is also one of the many reasons thousands of cardiovascular professionals travel far and wide to attend and hear first-hand the practice-changing research.

While there have been numerous practice-changing major randomized trials or large-scale observational studies over the years, we’ve gone through a list of over 400 trials, and picked out some of the top LBCTs from past Annual Scientific Session events. From these trials, we have learned more about antiplatelet therapy; that treatment with a percutaneous coronary intervention was not associated with a difference in death or MI compared with treatment with medical therapy; that transcatheter aortic valve replacement in patients with aortic stenosis demonstrated non-inferiority for all-cause mortality at 1 year compared to surgical aortic valve replacement; and much more.

What do you think are some of the top practice-changing trials to have been released at the College’s Annual Scientific Session? What research do you think currently in the works will shape the future of cardiology? Tell us at blog.cardiosource.org. It’s also not too late to submit science to be considered for ACC.14 in Washington, DC. LBCTs are due by Jan. 6, 2014. Also, don’t miss the three LBCT joint sessions with the Journal of the American College of Cardiology, Journal of the American Medical Association and New England Journal of Medicine planned for ACC.14. Visit accscientificsession.orgExternal Link for more information and to register for ACC.14.

Cannon is editor of CardioSource Science and Quality, and Bhatt and Eagle are associate editors of CardioSource Science and Quality.

The Top Late-Breaking Clinical Trials at ACC Annual Scientific Session, 2001 – 2013

ACC.01 | Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events: The CURE Trial

ACC.02 | A Prospective, Blinded Trial of B-Type Natriuretic Peptide as a Diagnostic Test for the Emergency Diagnosis of Heart Failure: The Breathing Not Properly (BNP) Multinational Study

ACC.03 | EPHESUS (Eplerenone Post-AMI Heart Failure Efficacy and Survival Study): A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Eplerenone in Patients With Heart Failure Following Acute Myocardial Infarction

ACC.03 | Cardiac Resynchronization Therapy Reduces Hospitalization and Cardiac Resynchronization Therapy an Implantable Defibrillator Reduces Mortality in Chronic Heart Failure: Results of the COMPANION Trial

ACC.04 | Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22 (PROVE IT - TIMI 22) – Statin Comparison

ACC.04 | Guidelines-Based Standardized Care Substantially Reduces Mortality in Medicare Patients With Acute Myocardial Infarction: The ACC’s Guidelines Applied in Practice Program in Michigan

ACC.05 | A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in 39,876 Women: The Women’s Health Study

ACC.05 | COMMIT/CCS-2: Placebo-Controlled Trial of Early Metoprolol in 46,000 Acute Myocardial Infarction Patients

ACC.06 | 1-Year Cardiovascular Event Rates in a Global Contemporary Registry of Over 68,000 Outpatients With Atherothrombosis: The Reduction of Atherothrombosis for Continued Health (REACH) Registry Results

ACC.07 | A Randomized Trial of Percutaneous Coronary Intervention Added to Optimal Medical Therapy in Patients With Stable Coronary Heart Disease: Results of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial

ACC.08 | Percutaneous Coronary Interventions at Facilities Without On-Site Cardiac Surgery: A Report From the NCDR

ACC.09 | CABG Versus CABG + SVR : Surgical Treatment for Ischemic Heart Failure (STICH) Trial

ACC.10 | Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The ACCORD Lipid Study

ACC.10 | Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial

ACC.10 | Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure: The RACE II Study

ACC.11 | Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement in “High Risk“ Patients with Aortic Stenosis: The Randomized PARTNER Trial

ACC.11 | Lifetime Cost Effectiveness of Transcatheter Aortic Valve Implantation Compared with Standard Care among Inoperable Patients with Severe Aortic Stenosis: Results: The PARTNER Trial (Cohort B)
Just Announced: ACC.14 Lecture Lineup
Gary H. Gibbons, MD

2014 Simon Dack Lecture
Gary H. Gibbons, MD
Charting our Future Together: Setting an Agenda for the NHLBI
Saturday, March 29, 8:00 – 10:00 a.m.
 
Prof. Murray Esler, AM, FAA, FRACP

45th Annual Bishop Lecture
Prof. Murray Esler, AM, FAA, FRACP
The Sympathetic Nervous System Moves Towards Center Stage in Cardiovascular Medicine: Catheter-Based Renal Denervation for Essential Hypertension
Saturday, March 29, 2:00 – 3:00 p.m.
 
Roberta G. Williams, MD, MACC

2014 Dan G. McNamara Lecture
Roberta G. Williams, MD, MACC
Congenital Landmarks: The Evolution of the Field
Sunday, March 30, 2014, 2:00 – 3:30 p.m.
 
Jessica L. Mega, MD, FACC

2014 Douglas P. Zipes, MD, MACC, Distinguished Young Scientist Award Lecture
Jessica L. Mega, MD, FACC
Limited Role for 2C19 Testing
Monday, March 31, 2014, 8:00 – 9:30 a.m.
 
Marilyn Tavenner

Invited 2014 James T. Dove Lecture
Marilyn Tavenner
CMS Specialty Payment Systems: Can We Switch from Volume to Value?
Monday, March 31, 2014, 10:45 a.m. – 12:15 p.m.
 
A. John Camm, MD, FACC

13th Annual Maseri-Florio International Lecture
A. John Camm, MD, FACC
Antiarrhythmic Drug Development — Done and Dusted?
Monday, March 31, 2014, 2:00 – 3:30 p.m.
 
Eugene Braunwald, MD, MACC

Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine
Eugene Braunwald, MD, MACC
The War on Heart Failure: News from the Front
Monday, March 31, 2014, 2:00 – 3:30 p.m.

Keywords: Washington, Heart Valve Prosthesis, Cardiology, New England, United States, Percutaneous Coronary Intervention


< Back to Listings